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a b s t r a c t
A notable feature of poxviruses is their ability to inhibit the antiviral response, including the nuclear
factor kappa B (NFκB) pathway. NFκB is a transcription factor that is sequestered in the cytoplasm until
cell stimulation, and relies on the SCF (Skp1, culllin-1, F-box) ubiquitin ligase to target its inhibitor, IκBα,
for degradation. IκBα is recruited to the SCF by the F-box domain-containing protein βTrCP. Here, we
show that ectromelia virus, the causative agent of mousepox, encodes four F-box-containing proteins,
EVM002, EVM005, EVM154, and EVM165, all of which contain Ankyrin (Ank) domains. The Ank/F-box
proteins inhibit NFκB nuclear translocation, and this inhibition is dependent on the F-box domain. We
also demonstrate that EVM002, EVM005, EVM154, and EVM165 prevent IκBα degradation, suggesting
that they target the SCF. This study identiﬁes a new mechanism by which ectromelia virus inhibits NFκB.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The nuclear factor kappa B (NFκB) family of transcription factors
regulates the expression of a number of genes, including those
involved in proliferation, apoptosis, and the innate and adaptive
immune response (Ghosh and Hayden, 2012; Hoffmann et al., 2003;
Vallabhapurapu and Karin, 2009). The NFκB pathway can be activated
by a number of stimuli; however, the best-studied are the classical
pathways that occur following the engagement of the pro-
inﬂammatory cytokines, TNFα and IL-1β, with the tumor necrosis
factor receptor (TNFR) and interleukin 1 receptor (IL-1R) or toll-like
receptor (TLR), respectively (Ghosh and Hayden, 2012; Hayden and
Ghosh, 2008, 2012). Receptor activation results in the recruitment of
adapter proteins and ubiquitin ligases that ultimately activate the
regulatory kinase complex, the inhibitor of κB (IκB) kinase (IKK)
complex, through phosphorylation. Following activation, the IKK
complex phosphorylates the inhibitor of κB (IκBα), which normally
sequesters the p65/p50 NFκB transcription factor in the cytoplasm.
Following phosphorylation, IκBα is recruited to the Skp1, cullin-1,
F-box (SCF) ubiquitin ligase by the F-box-containing protein βTrCP.
The SCF poly-ubiquitinates IκBα, targeting it for degradation by the
26S proteasome (Hatakeyama et al., 1999; Kroll et al., 1999;
Spencer et al., 1999). Left unsequestered by its inhibitor, IκBα, the
p65/p50 NFκB transcription factor is free to translocate into the
nucleus, where it stimulates gene transcription.
Signiﬁcantly, many viruses have evolved strategies to modulate
the NFκB pathway to ensure their own survival (Brady and Bowie,
2014; Mohamed and McFadden, 2009; Rahman and McFadden,
2011; Smith et al., 2013). The Poxviridae are a family of large
dsDNA viruses that are notorious for inhibiting the immune
response and regulating cellular signaling pathways (Brady and
Bowie, 2014; Johnston and McFadden, 2003; Moss and Shisler,
2001; Seet et al., 2003; Smith et al., 2013). Interestingly, a number
of inhibitors of the NFκB pathway have been identiﬁed in pox-
viruses, especially in the prototypic poxvirus vaccinia (Mohamed
and McFadden, 2009; Rahman and McFadden, 2011). Activation of
the NFκB pathway through the IL-1R is prevented by A52R, A46R,
and K7L (Bowie et al., 2000; Schroder et al., 2008). A46R binds the
TIR-domain containing adapter proteins MyD88, TRIF, TIRAP, and
TRAM, and prevents them from associating with the IL-1R (Bowie
et al., 2000; Stack et al., 2005). A52R and K7 bind TRAF6 and IRAK2
to disrupt signaling complexes containing these proteins (Bowie
et al., 2000; Graham et al., 2008; Harte et al., 2003; Schroder et al.,
2008). The IKK complex is targeted by N1L, B14R, and K1L (Chen
et al., 2006, 2008;; DiPerna et al., 2004; Shisler and Jin, 2004). N1L
interacts with multiple subunits of the IKK complex (DiPerna et al.,
2004), while B14R binds speciﬁcally to IKKβ (Chen et al., 2006,
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2008). Phosphorylation and subsequent activation of the IKK
complex are prevented by both N1L and B14R (Chen et al., 2008;
DiPerna et al., 2004). In contrast to N1L and B14R, K1L does not
interact with components of the IKK complex, instead it is thought
to inhibit unidentiﬁed kinases responsible for phosphorylating the
IKK complex (Shisler and Jin, 2004). Recently, A49 has also been
discovered to inhibit NFκB by acting as molecular mimic of IκBα
(Mansur et al., 2013). Vaccinia also encodes two additional
proteins that inhibit NFκB activation; M2L prevents ERK2 phos-
phorylation and subsequent signaling to the IKK complex (Gedey
et al., 2006; Hinthong et al., 2008), while E3L prevents NFκB
activation induced by the PKR pathway, following recognition of
viral double stranded RNA (Myskiw et al., 2009).
Using a bioinformatics screen, our lab identiﬁed four Ank/F-box
proteins, EVM002, EVM005, EVM154, and EVM165, in ectromelia virus
(Fig. 1A) (van Buuren et al., 2008). The combination of multiple Ank
domains in conjunction with a C-terminal F-box was unique to
poxviruses (Mercer et al., 2005; Sonnberg et al., 2008), until recently
when Ank/F-box proteins were identiﬁed in the parasitoid wasp,
Nasonia (Werren et al., 2010). Ank repeats are present in a number of
cellular proteins, and mediate distinctive protein–protein interactions
(Li et al., 2006). The F-box domain is necessary for interaction with
Skp1 in the SCF ubiquitin ligase, and cellular F-box proteins recruit
substrates to the SCF to be ubiquitinated (Kipreos and Pagano, 2000).
Interestingly, each protein has variation in the number and location of
the Ank repeats that it possesses, suggesting that these unique
combinations may allow the four proteins to interact with different
substrates.
Previously, our laboratory demonstrated that EVM005 associates
with the SCF ubiquitin ligase and inhibits NFκB signaling by preventing
degradation of IκBα (van Buuren et al., 2014, 2008). Since degradation
of IκBα is catalyzed by the SCFβTrCP ubiquitin ligase, we investigated
whether EVM002, EVM154, and EVM165 also inhibited NFκB activa-
tion. Here, we report that ectopic expression of EVM002, EVM005,
EVM154, and EVM165 inhibited TNFα- and IL-1β- induced NFκB
activation by preventing degradation of IκBα. However, deletion of
the F-box domain abrogated the ability of EVM002, EVM005, EVM154,
and EVM165 to inhibit NFκB activation. In addition, our studies
revealed that IκBα degradation and NFκB activationwere still inhibited
by ectromelia virus, even after deletion of the Ank/F-box. Our results
suggest that ectromelia virus encodes four additional inhibitors of the
NFκB pathway that modulate the SCFβTrCP ubiquitin ligase to prevent
degradation of IκBα.
Results
Ectromelia virus encodes four Ank/F-box proteins that are expressed
at both early and late times during infection
Recently, we demonstrated that EVM005 associates with the SCF
ubiquitin ligase and inhibits NFκB signaling by preventing degrada-
tion of IκBα (van Buuren et al., 2014, 2008). Since degradation of
IκBα is catalyzed by the SCFβTrCP ubiquitin ligase, we investigated
whether EVM002, EVM154, and EVM165 also inhibit NFκB activa-
tion. First, we wanted to verify if and when these genes were
transcribed during infection. To do this, we used semi-quantitative
reverse transcription PCR to examine mRNA levels during infection.
CV-1 cells were infected with ECTV and RNA was harvested at 4, 12,
and 24 h post-infection. Gene expression was assessed using
primers speciﬁc for EVM002, EVM004, EVM154, and EVM165. As
controls, we monitored transcript levels of EVM004 and EVM058.
EVM004 is a gene that is transcribed early during ECTV infection,
while EVM058 is transcribed late during ECTV infection (Wilton
et al., 2008). EVM004 transcripts were detected at 4, 12, and 24 h
post-infection (Fig. 1B). In the presence of AraC, an inhibitor of late
gene expression, EVM004 transcripts were still detected, indicating
that EVM004 was transcribed early during infection (Babiuk et al.,
1975; De Clercq et al., 1975) (Fig. 1B). In contrast to EVM004,
EVM058 transcripts were detected at only 12 and 24 h post-
infection, and detection was decreased in the presence of AraC,
indicating that EVM058 was transcribed late during infection
(Fig. 1B). Transcripts for EVM002, EVM005, and EVM165 were
detected at 4, 12, and 24 h post-infection, while EVM154 was not
detected until 12 h post-infection (Fig. 1B). Upon AraC treatment,
transcripts for EVM002, EVM005, and EVM165 were still detected,
while transcripts for EVM154 were no longer detected, indicating
that EVM154 was a late gene. Overall, these data indicated that
EVM002, EVM005, and EVM165 were transcribed early during
infection, while EVM154 was transcribed late during infection.
Fig. 1. EVM002, EVM005, and EVM165 are transcribed early during infection and EVM154 is transcribed late. (A) Schematic representation of EVM002, EVM005, EVM154,
and EVM165. (B) CV-1 cells are infected with ECTV at a MOI of 5 in the absence or presence of 80 mg/mL cytosine arabinoside (AraC). RNA is harvested at 4, 12, and 24 h post-
infection and gene transcription is assessed using gene-speciﬁc primers for EVM002, EVM005, EVM154 and EVM165. EVM004 is used as a control for early gene
transcription, EVM058 is used as a control for late gene transcription, and GAPDH is used as a loading control.
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EVM002, EVM005, EVM154 and EVM165 associate with the SCF
ubiquitin ligase in an F-box dependent manner
The presence of the F-box domain prompted us to determine
whether the Ank/F-box proteins associate with the SCF ubiquitin
ligase. The SCF ubiquitin ligase is composed of the RING-
containing protein Roc1, which possesses the ubiquitin ligase
activity (Petroski and Deshaies, 2005), and cullin-1, Skp1, and an
F-box-containing substrate adapter protein (Wertz and Dixit,
2008) (Fig. 2A). Cullin-1 acts as a molecular scaffold, interacting
with the linker protein Skp1. Substrate adapter proteins are
recruited to the SCF ubiquitin ligase via a protein–protein interac-
tion with the Skp1 linker (Cardozo and Pagano, 2004; Zheng et al.,
2002). The interaction between Skp1 and the substrate adapter
protein relies on the F-Box domain located on the adapter protein
(Cenciarelli et al., 1999). To determine if EVM002, EVM005,
EVM154, and EVM165 associate with Skp1, 293T cells were
co-transfected with plasmids expressing T7-tagged Skp1, and
either Flag-EVM002, Flag-EVM005, Flag-EVM154, or Flag-
EVM165. Alternatively, cells were co-transfected with plasmids
expressing Flag-EVM002(1–554), Flag-EVM005(1–593), Flag-
EVM154(F534A/P535A), or Flag-EVM165(1–566), all of which are
devoid of a functional F-box domain. Immunoprecipitation using
an antibody to T7 to pull down Skp1 indicated that full-length
EVM002, EVM005, EVM154, and EVM165 were associated with
Skp1 (Fig. 2A); however, deletion of the F-box domain abrogated
this interaction, indicating that the F-box was necessary for
association with Skp1.
EVM002, EVM005, EVM154 and EVM165 inhibit NFκB p65 nuclear
translocation
Upon NFκB activation, phosphorylated IκBα is ubiquitinated by
the SCFβTrCP ubiquitin ligase, resulting in the degradation of IκBα
(Hatakeyama et al., 1999; Kroll et al., 1999; Spencer et al., 1999).
Degradation of IκBα is crucial for translocation of NFκB into the
nucleus. Given that EVM002, EVM005, EVM154, and EVM165
associate with the SCF ubiquitin ligase (Fig. 2), we next wanted
to determine if they inhibited activation of the NFκB pathway.
To do this, we used immunoﬂuorescence microscopy to visualize
the localization of the NFκB subunit p65 (Fig. 3). HeLa cells were
mock- transfected or transfected with pcDNA3-Flag-EVM002,
pcDNA3-Flag-EVM005, pcDNA3-Flag-EVM154, or pcDNA3-Flag-
EVM165. Twelve hours post-transfection, cells were stimulated
with TNFα. Nuclei were detected with DAPI, and transfected cells
were detected using an antibody for Flag. Staining with an anti-
body to NFκB p65 revealed that p65 was dispersed throughout the
cytoplasm in mock-transfected cells (Fig. 3A, panels a–d), whereas
mock-transfected cells treated with TNFα displayed dramatic
accumulation of p65 in the nucleus (Salminen et al., 2008;
Schroder et al., 2008) (Fig. 3A, panels e–h). In contrast, cells
expressing EVM002, EVM005, EVM154, or EVM165 stimulated
with TNFα showed retention of p65 in cytoplasm (Fig. 3A, panels
i–x). The experiment was repeated using IL-1β to stimulate the
cells (data not shown). To quantify the percentage of cells
displaying p65 nuclear translocation, experiments were per-
formed in triplicate, and p65 nuclear translocation was quantiﬁed
by counting greater than 150 cells (Fig. 3B). Approximately 90% of
cells stimulated with TNFα or IL-1β displayed nuclear accumula-
tion of p65 (Fig. 3B). In cells transfected with the Ank/F-box
proteins, p65 accumulated in the nuclei of between 5% and 35%
of cells treated with TNFα or IL-1β. Overall, these data indicated
that EVM002, EVM005, EVM154, and EVM165 inhibit NFκB activa-
tion stimulated by TNFα or IL-1β.
Inhibition of NFκB activation is dependent on the F-box domain
Since association of EVM002, EVM005, EVM154, and EVM165
with the SCF ubiquitin ligase is dependent on the F-box domain
(Fig. 1), we wanted to determine if inhibition of NFκB by the
Fig. 2. EVM002, EVM005, EVM154, and EVM165 associate with Skp1 in the SCF
ubiquitin ligase. (A) Schematic of the SCF ubiquitin ligase. The SCF ubiquitin ligase
is a multi-subunit ubiquitin ligase. It contains an E3 ligase that transfers ubiquitin
to IκBα, the scaffold protein cullin-1, the linker protein Skp1, and a substrate
adapter protein containing an F-box domain. The F-box domain is crucial for
interaction with Skp1. The substrate adapter, βTrCP, recruits IκBα to the SCF
ubiquitin ligase. (B) The Ank/F-box proteins associate with Skp1. 293T cells are
co-transfected with T7-Skp1 and the Flag-tagged Ank/F-box proteins and their
mutants. Skp1 is immunoprecipitated using an anti-T7 antibody, and immunoblots
are performed using antibodies to detect the T7 and Flag tags.
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Ank/F-box proteins is dependent on the F-box domain. We repeated
the immunoﬂuorescence assay, transfecting HeLa cells with pcDNA3-
Flag-EVM002(1–554), pcDNA3-Flag-EVM005(1–593), pcDNA3-Flag-
EVM154(F534A/P535A), or pcDNA3-Flag-EVM165(1–566). Twelve
hours post-transfection, cells were stimulated with TNFα (Fig. 4) or
IL-1β (data not shown). Nuclei were detected with DAPI, and
transfected cells were detected using an antibody recognizing Flag.
Fig. 3. Expression of EVM002, EVM005, EVM154, and EVM165 prevent TNFα-
induced NFκB p65 nuclear translocation. (A) HeLa cells are mock-transfected (a–h),
or transfected with pcDNA3-Flag-EVM002 (i–l), pcDNA3-Flag-EVM005 (m–p),
pcDNA3-Flag-EVM154 (q–t), or pcDNA3-Flag-EVM165 (u–x). Twelve hours post-
transfection, cells are mock-stimulated (a–d) or stimulated with 10 ng/mL of TNFα
for 20 min (e–x). Endogenous p65 is detected with an antibody speciﬁc for p65, and
nuclei are detected with DAPI. (B) Ectromelia Ank/F-box proteins inhibit NFκB p65
nuclear translocation. To quantify NFκB p65 nuclear translocation, a total of 150
transfected cells are counted from three independent experiments and the
percentage of cells exhibiting NFκB p65 in the nucleus is calculated.
Fig. 4. EVM002, EVM005, EVM154, and EVM165 devoid of the F-box do not
prevent TNFα-induced NFκB p65 nuclear translocation. (A) HeLa cells are mock-
transfected (a–h), or transfected with pcDNA3-Flag-EVM002(1–554) (i–l), pcDNA3-
Flag-EVM005(1–593) (m–p), pcDNA3-Flag-EVM154(F534A/P535A) (q–t), or
pcDNA3-Flag-EVM165(1–566) (u–x). Twelve hours post-transfection, cells are
mock stimulated (a–d) or stimulated with 10 ng/mL of TNFα for 20 min (e–x).
Endogenous p65 is detected with an antibody speciﬁc for p65, and nuclei are
detected with DAPI. (B) Inhibition of NFκB p65 nuclear translocation by ectromelia
Ank/F-box proteins is dependent on the F-box domain. To quantify NFκB p65
nuclear translocation, a total of 150 transfected cells are counted from three
independent experiments and the percentage of cells exhibiting NFκB p65 in the
nucleus is calculated.
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Staining with an antibody to NFκB p65 revealed that, in contrast to
cells expressing full-length EVM002, EVM005, EVM154, or EVM165,
cells expressing EVM002(1–554), EVM005(1–593), EVM154(F534A/
P535A), or EVM165(1–566) displayed p65 nuclear translocation
following stimulationwith TNFα (Fig. 4A) and IL-1β (data not shown).
These data were quantiﬁed by performing the experiments in
triplicate and counting cells that contained p65 in the nucleus
(Fig. 4B). The percentage of cells transfected with EVM002(1–532),
EVM005(1–593), or EVM165(1–566) that contained p65 in the
nucleus was similar to that of stimulated mock-transfected cells,
while the percentage of cells transfected with EVM154(F534A/
P535A) containing p65 in the nucleus was slightly less (Fig. 4B).
Taken together, these data indicated that the F-box is important for
the ability of the Ank/F-box proteins to inhibit the classical NFκB
pathway.
The ectromelia virus Ank/F-box proteins prevent degradation of IκBα
Since EVM002, EVM005, EVM154, and EVM165 associated with
the SCF ubiquitin ligase, we wanted to determine if the Ank/F-box
proteins could inhibit IκBα degradation. To do this, we used
immunoﬂuorescence microscopy to visualize levels of IκBα in the
cell (Fig. 5A). HeLa cells were mock-transfected, or transfected
with pcDNA3-Flag-EVM002, pcDNA3-Flag-EVM005, pcDNA3-Flag-
EVM154, or pcDNA3-Flag-EVM165. Twelve hours post-transfec-
tion, cells were stimulated with TNFα. Nuclei were detected with
DAPI, and transfected cells were detected using an antibody for
Flag. Staining with an antibody to IκBα revealed that IκBα was
expressed at high levels in the cytoplasm of mock-transfected cells
(Fig. 5A, panels a–d), whereas mock-transfected cells treated with
TNFα displayed dramatic loss of IκBα (Fig. 5A, panels e–h).
In contrast, cells expressing Flag-EVM002, Flag-EVM005, Flag-
EVM154, or Flag-EVM165 stimulated with TNFα showed retention
of IκBα (Fig. 5A, panels i–x).
To further demonstrate that EVM002, EVM005, EVM154, and
EVM165 stabilized IκBα during activation of the NFκB pathway, we
used immunoblotting to monitor levels of IκBα (Fig. 5B). HeLa cells
were mock-transfected, or transfected with 3 μg of pcDNA3-Flag-
EVM002, pcDNA3-Flag-EVM005, pcDNA3-Flag-EVM154, or pcDNA3-
Flag-EVM165. Twelve hours post-transfection, cells were stimulated
with TNFα. Whole cells lysates were collected and immunoblotted to
detect changes in levels of IκBα. In mock-transfected cells, high levels
of IκBα were observed (Fig. 5B); however, levels of IκBα were
signiﬁcantly reduced following stimulation with TNFα, indicating
that IκBα was being degraded as a result of NFκB activation (Fig. 5B).
In transfected cells, Flag expression was detected, indicating trans-
fection, and increased levels of IκBα were observed following TNFα
stimulation, demonstrating that expression of the Ank/F-box pro-
teins could prevent degradation of IκBα (Fig. 5B). Overall, these data
indicated that EVM002, EVM005, EVM154, and EVM165 inhibited
degradation of IκBα during activation of the TNFα pathway.
Viruses devoid of EVM002 and EVM154 display a reduction
in plaque size
In order to understand more about the contribution of the Ank/
F-box proteins during infection, we generated four deletion
viruses, ECTVΔ002, ECTVΔ005, ECTVΔ154, and ECTVΔ165. Pre-
viously, we demonstrated that ectromelia virus devoid of EVM154,
and vaccinia virus devoid of B4R, the orthologue of EVM154,
displayed a reduced plaque size in tissue culture (Burles et al.,
2014). To determine if deletion of EVM002, EVM005, or EVM165
also resulted in a reduction in plaque size, we used a plaque assay
to compare plaque sizes (Fig. 8). CV-1 cells were infected with
ECTV, ECTVΔ002, ECTVΔ005, ECTVΔ154, or ECTVΔ165, and foci
were photographed at the indicated times post-infection. We
observed visible differences in foci size between ECTV and
ECVTΔ002, and ECTV and ECVTΔ154, and no differences between
ECTV and the ECTV devoid of EVM005 or EVM165 (Fig. 6A).
Statistical analyses revealed that the differences in foci size
between ECTV and ECVTΔ002, and ECTV and ECVTΔ154 were
signiﬁcant at all days post-infection, with p-Values of o0.001
(Fig. 6B).
Viruses devoid of EVM002, EVM005, EVM154, or EVM165 inhibit NFκB
p65 nuclear translocation
Poxviruses encode many inhibitors of the NFκB pathway
(Mohamed and McFadden, 2009; Rahman and McFadden, 2011);
however, ectromelia virus is missing a few of these inhibitors,
including A49, A52, K7, and M2 (Bowie et al., 2000; Gedey et al.,
2006; Hinthong et al., 2008; Schroder et al., 2008). Since we
demonstrated that EVM002, EVM005, EVM154, and EVM165
inhibited classical activation of the NFκB pathway (Fig. 3), we next
wanted to determine if deletion of the Ank/F-box proteins
decreased the ability of ectromelia virus to inhibit the NFκB
Fig. 5. Expression of EVM002, EVM005, EVM154, and EVM165 prevent TNFα-
induced IκBα degradation. (A) HeLa cells are mock-transfected (a–h), or transfected
with pcDNA3-Flag-EVM002 (i–l), pcDNA3-Flag-EVM005 (m–p), pcDNA3-Flag-
EVM154 (q–t), or pcDNA3-Flag-EVM165 (u–x). Twelve hours post-transfection,
cells are mock-stimulated (a–d), or stimulated with 10 ng/mL of TNFα for 20 min
(e–x). Endogenous IκBα is detected with an antibody speciﬁc for IκBα, and nuclei
are detected with DAPI. (B) Expression of EVM002, EVM005, EVM154, and EVM165
prevents TNFα-induced IκBα degradation. HeLa cells are mock-transfected (a–h), or
transfected with pcDNA3-Flag-EVM002 (i–l), pcDNA3-Flag-EVM005 (m–p),
pcDNA3-Flag-EVM154 (q–t), or pcDNA3-Flag-EVM165 (u–x). Twelve hours post-
transfection, cells are mock-stimulated (a–d) or stimulated with 10 ng/mL of TNFα
for 20 min (e–x). Endogenous IκBα is detected with an antibody speciﬁc for IκBα,
and nuclei are detected with DAPI.
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pathway. To do this, we used immunoﬂuorescence microscopy to
visualize the localization of the NFκB subunit p65 (Fig. 7A). HeLa
cells were mock-infected, or infected with ECTV, ECTVΔ002,
ECTVΔ005, ECTVΔ154, or ECTVΔ165. Twelve hours post-infection,
cells were stimulated with TNFα. Cells were stained with DAPI to
visualize nuclei and the DNA-rich virus factories surrounding the
nucleus, indicating infected cells. Staining with an antibody to
NFκB p65 revealed that p65 was dispersed throughout the
cytoplasm in mock-infected cells (Fig. 7A, panels a–c), whereas
mock-infected cells treated with TNFα displayed dramatic accu-
mulation of p65 in the nucleus (Fig. 7A, panels d–f) (Salminen
et al., 2008; Schroder et al., 2008). In contrast, cells infected with
ECTV displayed cytoplasmic retention of p65 following stimulation
(Fig. 7A, panels g–i). Cells infected with ECTVΔ002, ECTVΔ005,
ECTVΔ154, or ECTVΔ165 also displayed localization of p65 in the
cytoplasm following stimulation, indicating that deletion of a
single Ank/F-box gene was not enough to abrogate the ability of
ectromelia virus to inhibit NFκB activation (Fig. 7A, panels j–u).
The experiment was repeated using IL-1β to stimulate the cells
(data not shown), and ECTVΔ002, ECTVΔ005, ECTVΔ154, and
ECTVΔ165 inhibited nuclear translocation of NFκB following
stimulation with IL-1β.
To conﬁrm that ECTV devoid of EVM002, EVM005, EVM154, or
EVM165 inhibited NFκB, we generated nuclear and cytoplasmic
extracts to monitor NFκB p65 nuclear translocation. HeLa cells
were mock-infected, or infected with ECTV or the knockout
viruses. Twelve hours post-infection, cells were stimulated with
TNFα. Nuclear and cytoplasmic extracts were immunoblotted for
Fig. 6. ECTVΔ002 and ECTVΔ154 have reduced plaque sizes in CV-1 cells. (A) CV-1 cells are infected with ECTV (a–c), ECTVΔ002 (d–f), ECTVΔ005 (g–i), ECTVΔ154 (j–l), or
ECTVΔ165 (q–o). Cells are stained with crystal violet at 3 days (a, d, g, j, and q), 4 days (b, e, h, k, and n), or 5 days post-infection (c, f, i, l, and o). (B–D) Comparison of ECTV,
ECTVΔ002, ECTVΔ005, ECTVΔ154, and ECTΔ165 plaques in CV-1 cells. CV-1 cells are infected and stained with crystal violet 3, 4, or 5 days post-infection. Photographed
plaques are measured using ImageJ and analyzed using GraphPad to determine signiﬁcant differences in foci size between ECTV and the knockout viruses. Any signiﬁcant
differences between ECTV and the knockout viruses are listed above the knockout virus.
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NFκB p65, I5L, as a control to indicate virus infection (Sood et al.,
2008), and PARP and β-tubulin, as controls to indicate the purity of
the nuclear and cytoplasmic fractions, respectively (Machesky
et al., 1994; Smith et al., 1991). In mock-infected cells, a large
amount of p65 was detected in the cytoplasm, but very low levels
were detected in the nucleus (Fig. 7B). Following stimulation with
TNFα, high levels of p65 were observed in the nuclear fraction,
indicating that the NFκB pathway had been activated. Strikingly,
infected cells subjected to stimulation with TNFα displayed mini-
mal levels of p65 in the nuclear fraction, indicating that NFκB
activation was inhibited. The experiment was repeated using IL-1β,
and similar results were observed (data not shown). Overall, these
data indicated that ECTV devoid of EVM002, EVM005, EVM154, or
EVM165 inhibited TNFα and IL-1β p65 nuclear translocation.
Viruses devoid of EVM002, EVM005, EVM154, and EVM165 inhibit
IκBα degradation
Next, we sought to determine if the lack of any of the ECTV
Ank/F-box proteins prevented ECTVΔ002, ECTVΔ005, ECTVΔ154,
or ECTVΔ165 from inhibiting degradation of IκBα. To do this, we
used ﬂow cytometry to monitor levels of IκBα in infected cells,
following simulation with TNFα (Fig. 8). HeLa cells were mock-
infected, or infected with ECTV or the knockout viruses. Twelve
hours post-infection, cells were stimulated with TNFα, and ﬁxed
and stained with antibodies to IκBα, and I3L, as a control for virus
infection. Alternatively, mock-infected cells were pretreated with
the proteasome inhibitor MG132 prior to stimulation. MG132
prevents degradation of IκBα induced by TNFα (Traenckner et al.,
1994). Mock-infected cells exhibited high levels of IκBα, while cells
stimulated with TNFα displayed lower levels of IκBα, indicating
degradation (Fig. 8). Degradation of IκBα following TNFα stimula-
tion was prevented in cells that were pretreated with MG132,
since proteasomal activity was blocked (Traenckner et al., 1994).
Signiﬁcantly, cells infected with ECTV displayed no loss in IκBα,
indicating that degradation was prevented. Similar results were
also observed in cells infected with ECTVΔ002, ECTVΔ005,
ECTVΔ154, or ECTVΔ165. These data indicated that ectromelia
virus devoid of EVM002, EVM005, EVM154, or EVM165 still
prevent degradation of IκBα.
Fig. 7. ECTV, ECTVΔ002, ECTVΔ005, ECTVΔ154, and ECTVΔ165 inhibit TNFα-induced NFκB p65 nuclear translocation. (A) HeLa cells are mock-infected (a–f), or infected at a
MOI of 5 with ECTV (g–i), ECTVΔ002 (j–l), ECTVΔ005 (m–o), ECTVΔ154 (p–r), or ECTVΔ165 (s–u). Twelve hours post-infection, cells are mock-stimulated (a–c), or stimulated
with 10 ng/mL of TNFα for 20 min (d–u). Endogenous NFκB p65 was detected with an antibody speciﬁc for p65, and nuclei are detected with DAPI. (B) ECTV, ECTVΔ002,
ECTVΔ005, ECTVΔ154, or ECTVΔ165 inhibit TNFα-induced NFκB p65 nuclear translocation. HeLa cells are mock-infected (a–f), or infected at a MOI of 5 with ECTV (g–i),
ECTVΔ002 (j–l), ECTVΔ005 (m–o), ECTVΔ154 (p–r), or ECTVΔ165 (s–u). Twelve hours post-infection, cells are mock-stimulated (a–c), or stimulated with 10 ng/mL of TNFα
for 20 min (d–u). Endogenous NFκB p65 is detected with an antibody speciﬁc for p65, and nuclei are detected with DAPI.
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Discussion
Recently, we identiﬁed four Ank/F-box proteins encoded by
ectromelia virus, EVM002, EVM005, EVM154, and EVM165 (van
Buuren et al., 2008). Previous work from our lab had focused on
EVM005, and the purpose of this study was to build upon this
previous work, further extending our understanding of EVM005 to
the other three Ank/F-box proteins (van Buuren et al., 2014).
Interestingly, EVM002, EVM005, and EVM165 were expressed
early during infection, while EVM154 was expressed late (Fig. 1).
This temporal expression during virus infection suggests multiple
roles of the Ank/F-box proteins.
The NFκB signaling pathway is an important regulator of the
antiviral response (Hayden and Ghosh, 2008, 2012; Vallabhapurapu
and Karin, 2009). Importantly, a number of inhibitors of the NFκB
pathway have been identiﬁed in poxviruses (Brady and Bowie, 2014;
Mohamed and McFadden, 2009; Rahman and McFadden, 2011;
Smith et al., 2013). Translocation of NFκB into the nucleus is
dependent on the ubiquitination and degradation of IκBα, an event
that is tightly regulated by the SCFβTrCP ubiquitin ligase (Hatakeyama
et al., 1999; Kroll et al., 1999; Spencer et al., 1999). The presence of
the F-box domain suggested that EVM002, EVM005, EVM154, and
EVM165 might associate with Skp1 in the SCF ubiquitin ligase, and
this was in fact the case (Fig. 2). The association with Skp1 was
dependent on the F-box domain, since F-box null proteins did not
associate with Skp1 (Fig. 2).
The association of EVM002, EVM005, EVM154, and EVM165
with Skp1 prompted us to explore whether these proteins could
inhibit NFκB signaling. Using transient transfection and immuno-
ﬂuorescence experiments, we monitored the localization of the
NFκB subunit p65 following activation of the NFκB pathway. We
found that expression of EVM002, EVM005, EVM154, and EVM165
inhibited TNFα and IL-1β-induced p65 nuclear translocation
(Fig. 3). Signiﬁcantly, inhibition of this pathway was dependent
on the F-box domain, since deletion or mutation of this domain
prevented the Ank/F-box proteins from inhibiting TNFα and IL-1β-
induced p65 nuclear translocation (Fig. 4). Interestingly, although
the loss of the F-box domain decreased the ability EVM154 and
EVM165 to inhibit NFκB activation, these proteins still inhibited
this pathway to a greater extent than EVM002 or EVM005 did,
suggesting that EVM154 and EVM165 might not rely exclusively on
the F-box domain to inhibit NFκB.
Given the importance of the SCFβTrCP ubiquitin ligase in
regulating IκBα, we suspected that the association of EVM002,
EVM005, EVM154, and EVM165 with Skp1 might affect IκBα levels
in the cell. Using immunoﬂuorescence, we demonstrated that
expression of the Ank/F-box proteins prevented TNFα-induced
IκBα degradation (Fig. 5). Since the proteasome is active during
poxvirus infection (Fagan-Garcia and Barry, 2011), EVM002,
EVM005, EVM154, and EVM165 may prevent ubiquitination of
IκBα by interfering with the SCF ubiquitin ligase. In uninfected
cells, the cellular F-box protein βTrCP recruits phosphorylated IκBα
to the SCF ubiquitin ligase, and IκBα becomes ubiquitinated
(Hatakeyama et al., 1999; Kroll et al., 1999; Spencer et al., 1999).
The Ank/F-box proteins may compete with βTrCP for available
Skp1 in the SCF ubiquitin ligase. With less available Skp1 in the
cell, the interaction between βTrCP and the SCF ubiquitin ligase
would be diminished, thereby preventing IκBα ubiquitination and
subsequent degradation. This is not an uncommon mechanism,
since the HIV protein Vpu also prevents IκBα degradation by
disrupting binding to βTrCP and preventing the interaction
between Skp1 and βTrCP (Bour et al., 2001). Recently, the vaccinia
virus protein A49 was characterized, and it binds βTrCP in a similar
fashion to Vpu (Mansur et al., 2013). Interestingly, there is no
orthologue of A49 in ectromelia virus. We attempted to determine
if βTrCP and Skp1 still interact during infection with ectromelia
virus; however, our attempts were unsuccessful. Another possibi-
lity is that the Ank/F-box proteins target βTrCP for degradation.
This mechanism is used by the NSP1 protein family, a member of
which is encoded by some rotaviruses (Graff et al., 2009). Unfor-
tunately, we had difﬁculties detecting βTrCP, so we were unable to
determine whether βTrCP was degraded during infection with
ectromelia virus.
Degradation of IκBα occurs after the convergence point of many
NFκB signaling pathways. Thus, it is an attractive target for many
viruses that inhibit NFκB (Kim et al., 2008; Lei et al., 2010; Tait
et al., 2000). For instance, the 3C protease encoded by Coxsackie
virus cleaves IκBα to yield an N-terminal fragment bound to NFκB
dimer (Zaragoza et al., 2006). Although the fragmented IκB-NFκB
complex translocates into nucleus, it remains inactive and is
unable to activate gene transcription. HSV also encodes a protein
that targets IκBα. ICP27 binds to IκBα and prevents its phosphor-
ylation, thereby resulting in stabilization of IκBα (Kim et al., 2008).
African swine fever virus, on the other hand, induces degradation
of IκBα, which then allows the virus-encoded protein A238L to
interact with p65-containing NFκB dimers, preventing their
nuclear translocation (Tait et al., 2000). In addition, KSHV encodes
microRNAs that repress the expression of IκBα (Lei et al., 2010).
Fig. 8. Ectromelia virus devoid of the Ank/F-box proteins inhibits TNFα-induced IκBα degradation. (A) HeLa cells are mock-infected (a), or infected at an MOI of 5 with ECTV
(b, g), ECTVΔ002 (c, h), ECTVΔ005 (d, i), ECTVΔ154 (e, j), or ECTVΔ165 (f, k). Twelve hours post-infection, cells are mock-stimulated, or stimulated with 10 ng/mL TNFα for
20 min. Alternatively, mock-infected cells are treated with 10 mM of MG132 for 1 h prior to stimulation with TNFα. Cells are stained with an antibody speciﬁc for endogenous
IκBα (a–f), and an antibody speciﬁc for I3L (g–k), which was a control to indicate that infection had occurred.
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In order to understand the function of the Ank/F-box proteins
in the context of virus infection, we created four knockout viruses,
ECTVΔ002, ECTVΔ005, ECTVΔ154, and ECTVΔ165, each devoid of
a single Ank/F-box protein. As expected, we observed a reduction
in plaque size following infection of CV-1 cells with ECTVΔ154
(Fig. 6). Previously, we have suggested that EVM154 is important
for virion release or spread; however, the mechanism by which it
affects this remains unknown (Burles et al., 2014). Interestingly,
we also observed a reduction in plaque size following infection of
CV-1 cells with ECTVΔ002, perhaps suggesting a role for EVM002
in virion release or spread (Fig. 6). Since EVM002 is expressed
early during infection, it would be peculiar for it to affect a process
occurring late during infection; however, EVM002 is expressed
throughout infection, so this is a possibility.
We found that ectromelia viruses devoid of the Ank/F-box
proteins still inhibited p65 nuclear translocation induced by TNFα
(Fig. 7) and IL-1β (data not shown) and IκBα degradation (Fig. 8).
This was not surprising, since EVM002, EVM005, EVM154, and
EVM165 were transcribed at overlapping times during the course
of infection (Fig. 1), we expected that these four proteins might
exhibit some redundancy. So why would ectromelia virus encode
four proteins that inhibit NFκB by the same mechanism? Given the
variation in number and location of the Ank domains in the four
Ank/F-box proteins (Fig. 1), we suggest that the primary role for
EVM002, EVM005, EVM154, and EVM165 is substrate recruitment
to the SCF ubiquitin ligase, and inhibition of NFκB is a secondary
effect. That the Ank/F-box proteins have varied roles during
infection is possible. In fact, it has been demonstrated that
EVM002 affects stability of p105 (Rubio et al., 2013), and data
from our lab suggests that B4R, the vaccinia virus orthologue of
EVM154, may contribute to virion release (Burles et al., 2014).
Identiﬁcation of substrates will be detrimental to determining the
roles of the Ank/F-box proteins during infection.
Regulation of signaling is common amongst most viruses,
indicating the importance of the NFκB response to viral infection
(Hiscott et al., 2001, 2006; Mohamed and McFadden, 2009). We
demonstrated that ectromelia virus encodes four additional inhi-
bitors of the NFκB pathway. Evidence suggests that EVM002,
EVM005, EVM154, and EVM165 inhibit IκBα degradation through
modulation of the SCF ubiquitin ligase. In VACV, the orthologues of
EVM154 and EVM165, B4R and B18R, respectively, can be added to
the growing list of NFκB inhibitors.
Materials and methods
Cell lines and virus strains
CV-1, 293T, and HeLa cells were obtained from the American
Type Culture Collection (ATCC). U20S cells stably expressing a
cytoplasmic mutant of the Cre recombinase (U20S-Cre) were
kindly provided by Dr. J. Bell, University of Ottawa, Canada. Cells
were grown at 37 1C in 5% CO2 in Dulbecco's Modiﬁed Eagle
medium (DMEM) supplemented with 10% newborn calf serum
(NCS) (Invitrogen), 50 U/mL of penicillin (Invitrogen), 50 U/mL of
streptomycin (Invitrogen), and 200 μM of L-glutamine (Invitrogen).
Ectromelia virus strain Moscow (ECTV) was provided by
Dr. M. Buller (St. Louis University, USA). All viruses were propa-
gated in CV-1 cells as previously described (Stuart et al., 1991).
Plasmid constructs
pcDNA3-T7-Skp1 was described previously (Michel and Xiong,
1998). Construction of pcDNA3-Flag-EVM005 and pcDNA3-Flag-
EVM005(1–593) was previously described (van Buuren et al.,
2008). Codon optimized vectors were purchased from GENEART.
pMK-RQ-EVM002 contains from 50 to 30: a HindIII cut site, a Flag
sequence, an EcoRI cut site, the EVM002 sequence, and a BamHI
cut site. pMK-RQ-Flag-EVM154 contains from 50 to 30: a HindIII cut
site, a Flag sequence, an EcoRI cut site, the EVM154 sequence, and
a BamHI cut site. pMA-RQ-Flag-EVM165 contains from 50 to 30:
a HindIII cut site, a Flag sequence, an EcoRI cut site, the EVM165
sequence, and a BamHI cut site. Flag-tagged EVM002, EVM154, and
EVM165 were generated by digesting pMK-RQ-Flag-EVM002,
pMK-RQ-Flag-EVM154, and pMA-RQ-Flag-EVM165, respectively,
with HindIII and BamHI. The digestion products were ligated into
pcDNA3.1 (Invitrogen) using the HindIII and BamHI restriction
sites.
F-box deletion constructs were also generated. pcDNA3-Flag-
EVM002(1–554) was generated using pMK-RQ-Flag-EVM002 as a
PCR template with the following primers: forward 50-(HindIII)-
AAG CTT ATG GAC TAC AAA GAC GAT GAC GAC AAG GGC GAG ATG
GAC GAG ATC-30, and reverse 50-(BamHI)-GGA TCC TCA GCT GTA
GTA CTT GTA-30. The PCR product was subcloned into pGEM-T
(Promega) prior to ligation into pcDNA3.1, using the HindIII and
BamHI restriction sites. pcDNA3-Flag-EVM154(1–532) was gener-
ated using pMK-RQ-EVM154 as a PCR template using the following
primers: forward 50-(HindIII)-AAG CTT ATG GAC TAC AAA GAC GAT
GAC GAC AAG GAC TTC TTC AAG AAA GAG-30, and reverse
50-(BamHI)-GGA TCC TCA CCA CTT GTC GCC GGC GTC-30. The PCR
product was subcloned into pGEM-T prior to ligation into
pcDNA3.1, using the HindIII and BamHI restriction sites. Since we
could not express pcDNA3-Flag-EVM154(1–532), we generated
pcDNA3-Flag-EVM154(F534A/P535A). Phenyalanine 534 and pro-
line 535 in the F-box domain were mutated to alanine residues
using QuickChange II site directed mutagenesis, as per manufac-
turer's instructions (Stratagene). The mutations were introduced
using pcDNA-Flag-EVM154 as a PCR template with the following
primers: forward 50-GAC AAG TGG AGC TGC GCC GCC AAC GAG
ATC AAG-30, and reverse 50-CTT GAT CTC GTT GGC GGC GCA GCT
CCA CTT GTC-30. pcDNA3-Flag-EVM165(1–566) was generated
using pMA-RQ-Flag-EVM165 as a PCR template with the following
primers: forward 50-(HindIII)-GGA TCC ATG GAC TAC AAA GAC GAT
GAC GAC AAG AAC ATC AAG CAG CTG AAC-30, and reverse 50-
(BamHI)-GAA TCC TCA TCA CAG GGT CAG CAG ACA GTT-30. The PCR
product was subcloned into pGEM-T prior to ligation into
pcDNA3.1, using the HindIII and BamHI restriction sites.
pDGloxP was described previously (Rintoul et al., 2011). Con-
struction of pDGloxP-EVMΔ002 and pDGloxP-EVMΔ005 was pre-
viously described (Rintoul et al., 2011; van Buuren et al., 2014).
pDGloxP contains a yellow ﬂuorescent protein (YFP)/guanine
phosphoribosyltransferase (gpt) fusion open reading frame under
the control of a poxvirus early/late promoter. The promoter and
open reading frame are ﬂanked by loxP sites. pDGloxP-ΔEVM154
was constructed by PCR ampliﬁcation of the 200-nucleotide
sequences located directly upstream and downstream of EVM154
in the ECTV genome, using Taq polymerase (Invitrogen Corpora-
tion). The upstream region of homology was ampliﬁed using the
following primers: forward 50-(XhoI)-CTC GAG ATC ATA TAG ACA
ATA ACT-30 and reverse 50-(HindIII)-AAG CTT GAC ATA TAA TTT ATA
TTC TGT-30. The downstream region of homology was ampliﬁed
using the following primers: forward 50-(BamHI)-GGA TCC AAT
CTA AGT AGG ATA AAA-30 and reverse 50-(NotI)-GC GGC CGC AAA
CGA TGT TTC GGT AGA-30. The 400 base pair amplicons were
cloned into pGEM-T using the XhoI and HindIII restriction sites for
the upstream region, and BamHI and NotI for the downstream
region. The sequences were digested and subcloned into the
pDGloxP vector to create pDGloxP-ΔEVM154. pDGloxP-ΔEVM165
was constructed by PCR ampliﬁcation of the 200-nucleotide
sequences located directly upstream and downstream of EVM165
in the ECTV genome, using Taq polymerase (Invitrogen Corpora-
tion). The upstream region of homology was ampliﬁed using the
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following primers: forward 50-(XhoI)-CTG GAG ACT ATA GTA TTC
TGG ACT-30 and reverse 50-(HindIII)-AAG CTT TAT TAT AAA CGA
GTC CCA-30. The downstream region of homology was ampliﬁed
using the following primers: forward 50-(BamHI)-GGA TCC TTG
TAT TTT TAT CAT GTG-30 and reverse 50-(NotI)-GC GGC CGC GTA
TCT CTC ATT TTA TTG-30. The 400 base pair amplicons were cloned
into pGEM-T using the XhoI and HindIII restriction sites for the
upstream region, and BamHI and NotI for the downstream region.
The sequences were digested and subcloned into the pDGloxP
vector to create pDGloxP-ΔEVM165.
Generation of recombinant viruses
Construction of ECTVΔ002 and ECTVΔ005 was described pre-
viously (Rintoul et al., 2011; van Buuren et al., 2014). ECTVΔ154
and ECTVΔ165 were generated following a protocol described
previously (Rintoul et al., 2011). Brieﬂy, BGMK cells were infected
with ECTV at a MOI of 0.01 and transfected 1 h post-infection with
10 μg of linearized pDGloxP-ΔEVM154 or pDGloxP-ΔEVM165
using Lipofectamine 2000 (Invitrogen Corporation) (Gammon
et al., 2010; Rintoul et al., 2011). Recombinant viruses were
selected using media containing 25 μg/mL mycophenolic acid
(MPA) (Sigma-Aldrich), 250 μg/mL xanthine (Sigma-Aldrich), and
15 μg/μL hypoxanthine (Sigma-Aldrich). YFPþ recombinants were
screened visually using an inverted ﬂuorescent microscope (Leica).
The YFP/gpt-containing virus was passaged through U20S-Cre cells
and plaques were screened using the absence of YFP as an
indicator that excision by the Cre recombinase had occurred. PCR
analysis of viral genomes veriﬁed deletion of EVM154 and EVM165
from ECTV.
Semi-quantitative RT-PCR
RNA transcripts for EVM002, EVM005, EVM154, EVM165,
EVM004, EVM058, and GAPDH were analyzed as described pre-
viously (Wilton et al., 2008). CV-1 cells (1106) were mock-
infected or infected with ECTV at a MOI of 5. One hour post-
infection, media was removed, cells were washed with DMEM, and
1 mL of DMEM or DMEM containing 80 μg/mL of cytosine b-D-
arabinofuransoside hydrochloride (AraC) (Sigma-Aldrich) was
added later. Samples were collected 4, 12, and 24 h post-
infection by washing the cells with warm PBS and harvesting
with 1 mL of TRIZOL (Invitrogen). A mock sample was also
collected at the 12-h time point. cDNA was generated and used
as a template and gene-speciﬁc primers were used to amplify the
last 250 nucleotides (at the 30 end) of each open reading frame.
Transcripts were generated with the following primers: EVM002
forward primer 50-AGT CAT ACA TTC GGA CAA ACA-30, reverse
50-TTA TGA ATA ATA TTT GTA ATG GTT CTT TCC-30; EVM005
forward 50-TAG TGG TAT TAG AGA GAA ATG CAA TCT-30, reverse
50-TCA TTC ATG TGT CTG TGT TTG-30; EVM154 forward primer 50-
TAA TGA GAT ACG GTA GAC ATC CTT CTT-30, reverse 50-TTA TAT TTT
AAT AGT GTT TAT AAG ATT TTT TAG-30; EVM165 forward primer
50-CCT CAA TGA ATT AAA AAA ATA TAT TAA TGA TAC GTC-30,
reverse 50-CTA TAC TTT GGT AGA TGG ATA CGA TAT-30; EVM004
forward primer 50-GTT TAA TAT CAT GAA CTG CGA CTA TCT-30,
reverse 50-TTA ATA ATA CCT AGA AAA TAT TCC ACG AGC-30; and
EVM058 forward primer 50-ATG GCG GAT GCT ATA ACC GTT-30,
reverse 50-TTA ACT TTT CAT TAA TAG GGA-30.
Immunoprecipitation
293T cells were co-transfected with 3 μg of pcDNA3-T7-Skp1
and 2 μg of pcDNA3-Flag-EVM002, pcDNA3-Flag-EVM005,
pcDNA3-Flag-EVM154, or pcDNA3-Flag-EVM165, or the F-box null
constructs pcDNA3-Flag-EVM002(1–554), pcDNA3-Flag-EVM005
(1–593), pcDNA3-Flag-EVM154(F534A/P535A), or pcDNA3-Flag-
EVM165(1–566). Eighteen hours post-transfection, cells were
lysed in 1% NP-40 lysis buffer and subjected to immunoprecipita-
tion with mouse anti-T7 (Novagen) and protein G beads (GE
Healthcare). Proteins were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred on
to a nitrocellulose membrane (Fischer Scientiﬁc). Membranes were
blocked for 3 h at room temperature in 5% w/v skimmed milk
containing Tris-buffered saline with Tween 20 (TBS-T), containing
200 mM Tris (pH 7.5), 15 mM NaCl, and 0.1% v/v Tween-20 (Fischer
Scientiﬁc). Samples were immunoblotted and membranes were
incubated mouse anti-FlagM2 (1:5000) (Sigma-Aldrich) or mouse
anti-T7 (1:5000) (Novagen) in TBS-T overnight at 4 1C, and probed
with Peroxidase-conjugated AfﬁniPure goat anti-mouse (1:25,000)
(Jackson Laboratories). Proteins were visualized using enhanced
chemiluminescence (ECL) (GE Healthcare) and Amersham Hyer-
ﬁlm ECL (GE Healthcare).
Immunoﬂuorescence
HeLa cells (2105) were seeded on coverslips and mock-
transfected or transfected with 2 μg of the indicated plasmid
expressing a Flag-tagged protein. Alternatively, cells were mock-
infected or infected with the indicated virus at a MOI of 5.
Fourteen hours post-transfection or 12 h post-infection, cells were
stimulated with 10 ng/mL of TNFα (Roche) or IL-1β (Peprotech, Inc)
for 20 min. Following stimulation, cells were ﬁxed with 2% w/v
paraformaldehyde (Sigma-Aldrich) in PBS for 10 min, permeabi-
lized with 1% v/v NP-40 (Sigma-Aldrich) in PBS for 5 min, and
blocked with 30% v/v goat serum (Invitrogen) in PBS for 15 min.
Cells were incubated overnight with mouse anti-FlagM2 (1:200)
(Sigma-Aldrich) and rabbit anti-NFκB p65 (1:200) (Santa Cruz
Biotechnology). The cells were stained with goat anti-mouse
Alexaﬂour 488 (1:400) (Invitrogen) and goat anti-rabbit Alexaﬂour
546 (1:400) (Invitrogen). The cover slips were mounted in 50% v/v
glycerol containing 4 mg/mL N-propyl-gallate (Sigma-Aldrich) and
250 μg/mL 4,6-diamino-2-phenylindole (DAPI) (Invitrogen) to
visualize nuclei. Cells were visualized using the 40 oil immer-
sion objective of a Ziess Axiovert 200M ﬂuorescent microscope
outﬁtted with an ApoTome 10 optical sectioning device (Carl Zeiss,
Inc). NFκB p65 nuclear translocation was quantiﬁed by counting
150 Flag-positive cells over three independent trials.
Alternatively, HeLa cells (2105) were seeded on coverslips
and mock-transfected or transfected with 2 μg of pcDNA-Flag-
EVM002, pcDNA-Flag-EVM005, pcDNA-Flag-EVM154, or pcDNA-
Flag-EVM165. Fourteen hours post-transfection, cells were stimu-
lated with 10 ng/mL of TNFα. Cells were ﬁxed and permeabilized
as described above, and incubated with rabbit anti-Flag (1:200)
(Sigma-Aldrich) and mouse anti-IκBα (1:1000) (Cell Signaling
Technology) for 2 h. Cells were stained with goat anti-mouse
Alexaﬂour 488 (1:400) (Invitrogen) and goat anti-rabbit Alexaﬂour
546 (1:400) (Invitrogen), and visualized as described above.
Plaque assays
Viruses were serially diluted and titred on CV-1 cells (1106).
Plaques were allowed to form over 2–5 days and cells were stained
with crystal violet. Thirty randomly isolated plaques were photo-
graphed for each sample using an Axioscope 2 plus microscope
(Zeiss) at a magniﬁcation of 2.5 and measured in ImageJ v1.44i
(National Institutes of Health). The edge of the plaque (deﬁned by
the edge of cells that had piled) was traced using the shape tool in
ImageJ. The experiment was performed in triplicate. Plaque sizes
were compared using GraphPad Prism version 5 and statistical
signiﬁcance was determined using a one-way ANOVAwith a Tukey
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post-test (GraphPad Software, La Jolla California USA, www.graph
pad.com).
Nuclear and cytoplasmic extracts
HeLa cells (1106) were mock-infected or infected with the
indicated viruses at a MOI of 5. Twelve hours post-infection, cells
were stimulated with 10 ng/mL of TNFα or IL-1β at 37 1C for
20 min. Following stimulation, cells were washed with PBS and
collected by trypsinization. Cells were resuspended in 150 μL of
cold cytoplasmic extract buffer containing 10 mM HEPES, 10 mM
KCl, 0.1 mM EDTA (pH 8.0), 0.1 mM EGTA (pH 8.0), 1 mM dithio-
threitol (DTT), 0.05% v/v NP-40, and EDTA-free protease inhibitor
cocktail (Roche Diagnostics), and incubated at 4 1C for 30 min on a
rotator. Lysed cells were centrifuged at 1000g at 4 1C for 5 min and
the supernatant was collected and resuspended in 50 μL of 4X SDS
loading buffer containing 50% v/v glycerol, 20% v/v BME, 1% v/v
SDS, 312.5 mM Tris (pH 8.0), and 5 mg/mL bromophenol blue. The
pellet was washed with 150 μL cold cytoplasmic extract buffer and
centrifuged at 1000g at 4 1C for 5 min before being resuspended in
50 μL of cold nuclear extract buffer containing 20 mM HEPES, 25%
v/v glycerol, 0.4 M NaCl, 1 mM EDTA (pH 8.0), 1 mM EGTA (pH 8.0),
1 mM DTT, and EDTA-free protease inhibitor cocktail. The pellet
was brieﬂy vortexed, incubated on ice for 20 min, and centrifuged
at 18,000g at 4 1C for 10 min. The supernatant was collected and
resuspended in 20 μL of 4X SDS loading buffer. Samples were
immunoblotted with rabbit anti-NFκB p65 (1:5000) (Santa Cruz
Biotechnology), mouse anti-β-tubulin (1:5000) (ECM Biosciences),
mouse anti-PARP (1:2000) (BD Biosciences), and rabbit anti-I5L
(1:5000) (van Buuren et al., 2008).
Flow cytometry
HeLa cells (1106) were mock-infected or infected with the
indicated viruses at a MOI of 5. Twelve hours post-infection, cells
were stimulated with 10 ng/mL of TNFα at 37 1C for 20 min.
Alternatively, mock-infected cells were treated with 10 μM of the
proteasome inhibitor MG132 (Sigma-Aldrich) for 1 h prior to
stimulation with TNFα (Traenckner et al., 1994). Following stimu-
lation, cells were washed with PBS, then ﬁxed at 37 1C for 10 min
in 0.5% w/v paraformaldehyde in PBS and permeabilized with
cold 90% methanol on ice for 30 min. Cells were washed twice
with PBS containing 1% v/v HI-FBS, and stained for 1 h at room
temperature with mouse anti-IκBα (1:400) (Cell Signaling Tech-
nology) and mouse anti-I3L (1:100) diluted in 1% v/v FBS.
Cells were washed twice with PBS containing 1% v/v HI-FBS and
stained with phycoerythrin-conjugated goat anti-rabbit (1:1000)
(Jackson ImmunoResearch Laboratories Ltd.) and goat anti-mouse
Alexaﬂour 488 diluted (1:400) (Invitrogen Corporation) in 1%
v/v HI-FBS. Data were collected using a FACSan ﬂow cytometer
(Bectin Dickinson).
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